B. Nelson

9.0k total citations · 1 hit paper
12 papers, 1.0k citations indexed

About

B. Nelson is a scholar working on Oncology, Surgery and Molecular Biology. According to data from OpenAlex, B. Nelson has authored 12 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 5 papers in Surgery and 5 papers in Molecular Biology. Recurrent topics in B. Nelson's work include Bladder and Urothelial Cancer Treatments (5 papers), Urinary and Genital Oncology Studies (5 papers) and Melanoma and MAPK Pathways (5 papers). B. Nelson is often cited by papers focused on Bladder and Urothelial Cancer Treatments (5 papers), Urinary and Genital Oncology Studies (5 papers) and Melanoma and MAPK Pathways (5 papers). B. Nelson collaborates with scholars based in United States, France and Netherlands. B. Nelson's co-authors include William Novotny, R. Mass, Fairooz F. Kabbinavar, Michael McCleod, Taral Patel, Joseph J. Schulz, J. Randolph Hecht, John Hamm, Margitta Retz and Yohann Loriot and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Urology.

In The Last Decade

B. Nelson

12 papers receiving 1000 citations

Hit Papers

Addition of Bevacizumab to Bolus Fluorouracil and Leucovo... 2005 2026 2012 2019 2005 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Addition of Bevacizumab to Bolus Fluorouracil and Leucovorin in First-Line Metastatic Colorectal Cancer: Results of a Randomized Phase II Trial
    2005 709 citations Fairooz F. Kabbinavar, Joseph J. Schulz et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
B. Nelson United States 7 795 295 278 199 167 12 1.0k
L. Leong United States 16 648 0.8× 199 0.7× 241 0.9× 188 0.9× 238 1.4× 41 1.0k
Daniel Rauch Switzerland 20 711 0.9× 149 0.5× 385 1.4× 156 0.8× 221 1.3× 53 1.1k
Seta Shahin United States 8 812 1.0× 120 0.4× 319 1.1× 186 0.9× 110 0.7× 13 948
Tarek Chidiac United States 11 802 1.0× 207 0.7× 384 1.4× 187 0.9× 102 0.6× 16 1.0k
B. Mirtsching United States 12 1.1k 1.4× 182 0.6× 459 1.7× 131 0.7× 131 0.8× 27 1.3k
Epaminontas Samantas Greece 18 857 1.1× 248 0.8× 621 2.2× 68 0.3× 232 1.4× 62 1.2k
M. E. Vega-Villegas Spain 9 951 1.2× 152 0.5× 562 2.0× 226 1.1× 274 1.6× 17 1.2k
Clara Montagut Spain 10 716 0.9× 182 0.6× 229 0.8× 58 0.3× 356 2.1× 13 934
Masahito Kotaka Japan 19 841 1.1× 98 0.3× 389 1.4× 134 0.7× 320 1.9× 110 1.0k
Yousif Abubakr United States 6 1.1k 1.4× 122 0.4× 498 1.8× 334 1.7× 192 1.1× 7 1.2k

Countries citing papers authored by B. Nelson

Since Specialization
Citations

This map shows the geographic impact of B. Nelson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. Nelson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. Nelson more than expected).

Fields of papers citing papers by B. Nelson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B. Nelson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. Nelson. The network helps show where B. Nelson may publish in the future.

Co-authorship network of co-authors of B. Nelson

This figure shows the co-authorship network connecting the top 25 collaborators of B. Nelson. A scholar is included among the top collaborators of B. Nelson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B. Nelson. B. Nelson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
2.
Rosenberg, Jonathan E., Matthew D. Galsky, Arjun Vasant Balar, et al.. (2021). 699P Atezolizumab monotherapy in cisplatin-ineligible patients with previously untreated metastatic urothelial carcinoma: 5-year response and survival analysis from the phase II IMvigor210 study (cohort 1). Annals of Oncology. 32. S711–S712. 5 indexed citations
3.
4.
Perez‐Gracia, José Luis, Yohann Loriot, Jonathan E. Rosenberg, et al.. (2017). Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. European Urology. 73(3). 462–468. 31 indexed citations
5.
Castellano, Daniel, Peter Albers, Juergen E. Gschwend, et al.. (2016). 1143 A phase III study of the efficacy and safety of adjuvant atezolizumab (anti-PDL1) vs observation in patients with muscle-invasive urothelial carcinoma of the bladder (IMvigor 010). European Urology Supplements. 15(3). e1143–e1143. 3 indexed citations
6.
Lacouture, Mario E., Madeleine Duvic, Axel Hauschild, et al.. (2013). Analysis of Dermatologic Events in Vemurafenib-Treated Patients With Melanoma. The Oncologist. 18(3). 314–322. 156 indexed citations
7.
Chapman, Paul B., Axel Hauschild, Caroline Robert, et al.. (2011). Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor RG7204 with dacarbazine in patients with V600E BRAF-mutated melanomas.. Journal of Clinical Oncology. 29(15_suppl). LBA4–LBA4. 2 indexed citations
8.
Chapman, Paul B., Axel Hauschild, Caroline Robert, et al.. (2011). Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600E BRAF-mutated melanoma. 13 indexed citations
9.
McArthur, Grant A., Axel Hauschild, Caroline Robert, et al.. (2011). Vemurafenlb Improves Overall Survival Compared to Dacarbazlne In Advanced BRAFV600E-mutated Melanoma: Updated Survival Results From a Phase III Randomised, Open-label, Multlcentre Trial. European Journal of Cancer. 47. 14–14. 4 indexed citations
10.
Chapman, Paul B., Axel Hauschild, Caroline Robert, et al.. (2011). Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma.. Journal of Clinical Oncology. 29(18_suppl). LBA4–LBA4. 19 indexed citations
11.
Kabbinavar, Fairooz F., Joseph J. Schulz, Michael McCleod, et al.. (2005). Addition of Bevacizumab to Bolus Fluorouracil and Leucovorin in First-Line Metastatic Colorectal Cancer: Results of a Randomized Phase II Trial. Journal of Clinical Oncology. 23(16). 3697–3705. 709 indexed citations breakdown →
12.
Novotny, William, Eric Holmgren, B. Nelson, et al.. (2004). Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) does not increase the incidence of venous thromboembolism when added to first-line chemotherapy to treat metastatic colorectal cancer. Journal of Clinical Oncology. 22(14_suppl). 3529–3529. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by L. Leong Breakdown of academic impact, for papers by Daniel Rauch Breakdown of academic impact, for papers by Seta Shahin Breakdown of academic impact, for papers by Tarek Chidiac Breakdown of academic impact, for papers by B. Mirtsching Breakdown of academic impact, for papers by Epaminontas Samantas Breakdown of academic impact, for papers by M. E. Vega-Villegas Breakdown of academic impact, for papers by Clara Montagut Breakdown of academic impact, for papers by Masahito Kotaka Breakdown of academic impact, for papers by Yousif Abubakr
Rankless by CCL
2026